View in EDS

Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.

Saved in:
Bibliographic Details
Title: Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
Authors: Lal, Himal1 himallal@yahoo.com, Poder, Airi2 airi.poder@std.ee, Campora, Laura3 laura.e.campora@gsk.com, Geeraerts, Brecht3 brecht.r.geeraerts@gsk.com, Oostvogels, Lidia3 lidia.oostvogels@gsk.com, Vanden Abeele, Carline3 carline.c.vanden-abeele@gsk.com, Heineman, Thomas C.1 thomas.heineman@genocea.com
Source: Vaccine. Jan2018, Vol. 36 Issue 1, p148-154. 7p.
Database: Environment Complete
Description
ISSN:0264410X
DOI:10.1016/j.vaccine.2017.11.019